Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Orchestra BioMed Holdings, Inc.'s return on equity, or ROE, is -289.42% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that OBIO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
OBIO 2.44 -0.07(-2.79%)
Will OBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for OBIO
The technical outlook for OBIO is unchanged after it falls 2.79% on September 19
Stochastic Buy Signal appears for OBIO after 2.03% move
Technical picture remains unchanged for OBIO after it falls 2.77% on September 17
OBIO falls 2.69% on September 16, leaving the technical picture intact
Is OBIO signaling selling opportunity? 20 Day Moving Average Resistance shows up after rising 1.17%